To the full analysis
Buyback calculator for Nektar Therapeutics
Nektar Therapeutics stock: key metrics
NKTRNektar Therapeutics had an operating margin of −236.8% and a return on invested capital (ROIC) of −42.2% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 45.8% | −73.1% | −71.1% |
| 2007 | 46.0% | −13.2% | −12.0% |
| 2008 | 61.1% | −91.6% | −38.1% |
| 2009 | 57.0% | −132.3% | −142.5% |
| 2010 | 83.9% | −17.8% | −23.9% |
| 2011 | 69.4% | −173.4% | −187.4% |
| 2012 | 62.5% | −173.9% | −211.7% |
| 2013 | 74.1% | −80.7% | −108.8% |
| 2014 | 85.8% | −8.2% | −26.9% |
| 2015 | 85.2% | −12.7% | −35.2% |
| 2016 | 81.7% | −68.2% | −92.8% |
| 2017 | 90.1% | −19.4% | −31.4% |
| 2018 | 98.0% | 57.6% | 57.1% |
| 2019 | 81.4% | −383.9% | −384.5% |
| 2020 | 87.3% | −248.5% | −290.6% |
| 2021 | 75.6% | −437.8% | −514.0% |
| 2022 | 76.5% | −261.0% | −400.0% |
| 2023 | 59.3% | −152.5% | −306.3% |
| 2024 | 68.8% | −106.9% | −120.9% |
| 2025 | 100.0% | −236.8% | −297.1% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −68.2% | −60.9% | −20.1% |
| 2007 | −15.3% | −20.6% | −4.5% |
| 2008 | −18.1% | −14.7% | −6.1% |
| 2009 | −100.0% | −16.4% | −17.8% |
| 2010 | −41.8% | −5.1% | −7.3% |
| 2011 | −67.7% | −19.5% | −22.1% |
| 2012 | −100.0% | −23.1% | −34.5% |
| 2013 | 180.2% | −25.1% | −37.3% |
| 2014 | −100.0% | −3.6% | −12.2% |
| 2015 | −100.0% | −5.7% | −16.2% |
| 2016 | −100.0% | −19.0% | −27.0% |
| 2017 | −100.0% | −9.9% | −19.0% |
| 2018 | 39.7% | 206.1% | 31.7% |
| 2019 | −31.4% | −62.2% | −22.3% |
| 2020 | −41.3% | −91.7% | −28.9% |
| 2021 | −77.1% | −28.7% | −46.9% |
| 2022 | −100.0% | −22.7% | −51.8% |
| 2023 | −100.0% | −22.0% | −69.4% |
| 2024 | −100.0% | −28.2% | −39.2% |
| 2025 | −100.0% | −42.2% | −58.5% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2019)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.